Compare KE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | CADL |
|---|---|---|
| Founded | 1961 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.4M | 694.6M |
| IPO Year | 2014 | 2021 |
| Metric | KE | CADL |
|---|---|---|
| Price | $24.56 | $10.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $28.00 | $19.00 |
| AVG Volume (30 Days) | 215.1K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,486,727,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.04 | $4.35 |
| 52 Week High | $33.19 | $11.36 |
| Indicator | KE | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 57.11 |
| Support Level | $23.65 | $4.80 |
| Resistance Level | $26.87 | $11.36 |
| Average True Range (ATR) | 1.07 | 0.61 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 39.12 | 64.29 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.